Table 7.

Mean fasting plasma glucose and HbA1c in participants with non - diabetic hyperglycemia ^a or impaired fasting glucose where glycemic category changed (progressed or regressed), or remained unchanged, on a repeat second baseline sample taken a median 40 days later^a.

	Regressed	Unchanged	Progressed	Overall p
Non diabetic hyperglycemia
n	312	1047	104
Fasting plasma glucose (mmol/L)	5.6 (0.6)***	5.9 (0.6)	6.1 (0.7)***	0.0001
HbA1c % (mmol/mol)	42.8 (1.1)***	43.9 (1.4)	45.4 (1.4)***	0.0001
HbA1c (%)	6.1 (0.1)***	6.2 (1.4)	6.3 (1.4)***
Impaired fasting glucose
n	343	494	113
Fasting plasma glucose (mmol/L)	6.3 (0.2)***	6.4 (0.2)	6.6 (0.2)***	0.0001
HbA1c % (mmol/mol)	42.0 (3.9)***	44.2 (4.3)	46.6 (4.4)***	0.0001
HbA1c (%)	6.10 (0.36)***	6.2 (4.3)	6.4 (4.4)***

^aNon diabetic hyperglycemia (NDH) on first sample defined as HbA1c ≥6% (≥42–<48 mmol/mol) and impaired fasting plasma glucose as ≥6.1 mmol/L–<7.0 mmol/l. The term regression means the second baseline sample was HbA1c <6% (<42 mmol/mol) or fasting plasma glucose <6.1 mmol/L on repeat baseline sample. The term progression means the second baseline sample was HbA1c ≥6.5% (≥48 mmol/mol) or fasting plasma glucose ≥7.0 mmol/L. Median 40 days (interquartile range 27–69 days) between paired baseline data. Please note total sample size (n = 950) for IFG is slightly lower than in Tables 1–3 as repeat sample not undertaken.

***p < 0.001 compared to unchanged group. Across group comparisons by one-way ANOVA model, and two-way comparison is based on an independent samples test. Data shown as mean (SD).